Puma Biotechnology (PBYI) Income from Continuing Operations (2017 - 2025)
Historic Income from Continuing Operations for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $8.8 million.
- Puma Biotechnology's Income from Continuing Operations fell 5647.0% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.9 million, marking a year-over-year increase of 2866.49%. This contributed to the annual value of $23.2 million for FY2024, which is 746.61% up from last year.
- Latest data reveals that Puma Biotechnology reported Income from Continuing Operations of $8.8 million as of Q3 2025, which was down 5647.0% from $5.9 million recorded in Q2 2025.
- Puma Biotechnology's 5-year Income from Continuing Operations high stood at $20.3 million for Q3 2024, and its period low was -$44.7 million during Q3 2021.
- For the 5-year period, Puma Biotechnology's Income from Continuing Operations averaged around $1.8 million, with its median value being $3.0 million (2025).
- Per our database at Business Quant, Puma Biotechnology's Income from Continuing Operations surged by 171000.0% in 2023 and then tumbled by 44368.31% in 2024.
- Quarter analysis of 5 years shows Puma Biotechnology's Income from Continuing Operations stood at $4.2 million in 2021, then crashed by 232.72% to -$5.6 million in 2022, then skyrocketed by 318.84% to $12.3 million in 2023, then decreased by 0.31% to $12.2 million in 2024, then fell by 27.69% to $8.8 million in 2025.
- Its Income from Continuing Operations stands at $8.8 million for Q3 2025, versus $5.9 million for Q2 2025 and $3.0 million for Q1 2025.